ONCTERNAL THERAPEUTICS INC

Oncternal Therapeutics, Inc. (http://www.oncternal.com/) is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology therapies for the treatment of cancers with unmet medical need. The Company’s clinical pipeline includes cirmtuzumab, TK216, ROR1 CAR-T. Cirmtuzumab is a monoclonal antibody that is designed to inhibit Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1) for the treatment of patients with B-cell lymphoid malignancies, including mantle cell lymphoma (MCL), and chronic lymphocytic leukemia (CLL). TK216 is a small molecule inhibiting the biological activity of E26 transformation-specific (ETS)-family transcription factor oncoproteins. The Company is also developing a ROR1-targeted CAR-T cell therapy candidate utilizing the binding domain of cirmtuzumab as a single-chain variable region fragment (scFv) for the treatment of patients with hematological malignancies or solid tumors.

• ONCTERNAL THERAPEUTICS INC